FASTKD1 as a diagnostic and prognostic biomarker for STAD: Insights into m6A modification and immune infiltration
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Fas-activated serine/threonine kinase domain 1 (FASTKD1) is upregulated in stomach adenocarcinoma (STAD), correlating with poor prognosis and influencing immune infiltration and m6A modification. This suggests FASTKD1 as a potential biomarker for STAD.
Area Of Science
- Oncology
- Molecular Biology
- Immunology
Background
- Fas-activated serine/threonine kinase domain 1 (FASTKD1) modulates mitochondrial cell death and survival.
- The role of FASTKD1 in gastric cancer (stomach adenocarcinoma, STAD) is not well understood.
- Investigating FASTKD1's expression and function in STAD is crucial for understanding gastric cancer biology.
Purpose Of The Study
- To investigate the expression of FASTKD1 in STAD.
- To analyze the association between FASTKD1 expression and clinicopathological characteristics, immune infiltration, and m6A modification in STAD.
- To evaluate FASTKD1 as a potential diagnostic and prognostic biomarker for STAD.
Main Methods
- Analysis of FASTKD1 expression in STAD and normal tissues using TCGA and GEO databases.
- Validation through immunohistochemical staining.
- Co-expression analysis, GO/KEGG enrichment, GSEA, and LinkedOmics analysis.
- Exploration of immune infiltration and m6A modification correlations using TIMER, GEPIA, GEO, and TCGA.
Main Results
- FASTKD1 was significantly upregulated in STAD and accurately distinguished tumor from normal tissues.
- FASTKD1 expression correlated significantly with clinical stage and patient survival.
- Genes co-expressed with FASTKD1 were involved in diverse biological processes.
- FASTKD1 expression showed an inverse correlation with immune cell infiltration.
- Significant correlations were found between FASTKD1 and m6A modification genes (YTHDF1, LRPPRC).
Conclusions
- FASTKD1 plays a significant role in m6A modification and immune infiltration in STAD.
- FASTKD1 is a potential diagnostic and prognostic biomarker for stomach adenocarcinoma.
- Further research into FASTKD1's mechanisms in STAD is warranted.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.